2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Aminotransferases (Transaminases)

Aminotransferases (Transaminases)

Aminotransferases (Transaminases)

Aminotransferases (transaminases) are enzymes that catalyze a transamination reaction between amino acids and α-keto acids. They mainly include glutamate-pyruvate transaminase (GPT), also known as alanine aminotransferase (ALT), and glutamate-oxaloacetate transaminase (GOT), also known as aspartate aminotransferase (AST). Aminotransferases (transaminases) play a crucial role in the biosynthesis of non-essential amino acids, helping cells generate the required amino acids by transferring amino groups. Aminotransferases (transaminases) are also involved in the nitrogen-containing compounds metabolism, converting amino acids into forms that are easily excreted or can be used in other metabolic pathways. ALT and AST are often used as clinical diagnostic indicators. An increase in their levels in the blood is often associated with liver diseases such as hepatitis and cirrhosis, heart diseases such as myocardial infarction, and muscle diseases such as polymyositis[1][2].

Aminotransferases (Transaminases) Related Products (12):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-141669
    BCAT-IN-2
    		Inhibitor 99.07%
    BCAT-IN-2 is a potent, selective and orally active inhibitor of mitochondrial branched-chain aminotransferase (BCATm), with a pIC50 of 7.3. BCAT-IN-2 shows selectivity for BCATm over BCATc (pIC50=6.6). BCAT-IN-2 can be used for the research of obesity and dislipidema.
    BCAT-IN-2
  • HY-116451
    PF-04859989 hydrochloride
    		Inhibitor 99.90%
    PF-04859989 hydrochloride is a brain-penetrant, irreversible kynurenine aminotransferase (KAT) II inhibitor with IC50s of 23 and 263 nM for hKAT II and rKAT II. PF-04859989 hydrochloride is selective for KAT II over human KAT I, KAT III, and KAT IV (IC50s of 22, 11, and >50 μM, respectively).
    PF-04859989 hydrochloride
  • HY-116044
    BCATc Inhibitor 2
    		Inhibitor 99.83%
    BCATc Inhibitor 2 is a selective branched-chain aminotransferase (BCAT) inhibitor for research of neurodegenerative diseases. The IC50s of 0.2 μM, 0.8 μM and 3.0 μM for rat cytosolic isoenzyme rBCATc, human cytosolic isoenzyme hBCATc and rat mitochondrial isoenzyme rBCATm, respectively. BCATc, also called BCAT1, is in the cytoplasm.
    BCATc Inhibitor 2
  • HY-121212
    Icosabutate
    Icosabutate, an orally active ω-3 polyunsaturated fatty acid, is an aeicosapentaenoic acid (EPA) derivative. Icosabutate overcomes the drawbacks of unmodified EPA for liver targeting and improves insulin sensitivity, hepatic inflammation and fibrosis. Icosabutate is well tolerated, and efficacious in lowering non-high-density lipoprotein cholesterol (non-HDL-C) levels in persistent?hypertriglyceridemia?.
    Icosabutate
  • HY-141668
    BCAT-IN-1
    		Inhibitor
    BCAT-IN-1 is a potent, selective and orally active inhibitor of BCATm, with a pIC50 of 7.3. BCAT-IN-1 shows 100-fold selectivity for BCATm over BCATc (pIC50=5.4). BCAT-IN-1 can be used for the research of metabolic diseases.
    BCAT-IN-1
  • HY-168429
    3HKT-IN-1
    		Inhibitor
    3HKT-IN-1 (Compound 17122279) is an Anopheles gambiae 3-hydroxykynurenine transaminase (3HKT) inhibitor. 3HKT-IN-1 can be used for Malaria research.
    3HKT-IN-1
  • HY-171035
    PRL-295
    		Inhibitor
    PRL-295 is an orally active inhibitor targeting Keap1-Nrf2 interaction。PRL-295 increases the thermal stability of Keap1 and disrupts its interaction with Nrf2, thereby activating the Nrf2-dependent transcriptional target NAD(P)H:quinone oxidoreductase 1 (NQO1). PRL-295 protects against Acetaminophen (HY-66005)-induced liver injury in mice.
    PRL-295
  • HY-169792
    HPG1860
    		Inhibitor
    HPG1860 is an orally active, highly selective and potent FXR agonist, with an EC50 of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC50 values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH).
    HPG1860
  • HY-156962
    BFF-816
    		Inhibitor ≥98.0%
    BFF-816 is an orally active kynurenine aminotransferase II (KAT II) inhibitor. BFF-816 can be used in the research of the neurobiology of KYNA.
    BFF-816
  • HY-158309
    hOAT-IN-1
    		Inhibitor
    hOAT-IN-1 (compound 5) is a mechanical inhibitor of human ornithine aminotransferase (hOAT). hOAT-IN-1 as a time-dependent inhibitor can form tightly bound PLP inhibitor adduct with hOAT. hOAT-IN-1 can result IN tight occupation of the active site of hOAT. hOAT-IN-1 can be used in the study of lung cell carcinoma .
    hOAT-IN-1
  • HY-159730
    ERG245
    		Inhibitor
    ERG245 is a BCAT1 inhibitor that enhances oxidative phosphorylation (OXPHOS) in CD8+ T cells by specifically inhibiting BCAT1 activity, thereby increasing the cytotoxicity of CD8+ T cells. ERG245, in combination with Pembrolizumab (anti-PD-1, HY-P9902A), promotes tumor regression. ERG245 can be used in research related to immuno-oncology.
    ERG245
  • HY-113967
    PF-04859989
    		Inhibitor
    PF-04859989 is a brain-penetrant, irreversible kynurenine aminotransferase (KAT) II inhibitor with IC50s of 23 and 263 nM for hKAT II and rKAT II. PF-04859989 is selective for KAT II over human KAT I, KAT III, and KAT IV (IC50s of 22, 11, and >50 μM, respectively).
    PF-04859989